When researchers from Texas A&M and colleagues published a 2025 narrative review in Obesity Pillars, they weren’t just offering another supplement checklist. They were drawing attention to a problem that most GLP-1 prescribers aren’t talking about loudly enough: the medications work remarkably well for fat loss — achieving 15% or more body weight reduction in many patients — but that weight doesn’t come off as cleanly as we’d like. Alongside the fat, lean muscle mass walks out the door too. And that’s where creatine monohydrate enters the conversation in a serious, evidence-backed way.
This isn’t a niche concern for a small subset of men. Whether you’re using a GLP-1 receptor agonist like semaglutide or tirzepatide, grinding through a caloric deficit the old-fashioned way, or deep into a body recomposition phase, preserving muscle during fat loss is one of the most consequential things you can do for your long-term health, metabolism, and physical capacity. Creatine — arguably the most studied ergogenic supplement in existence — has a compelling and growing role in that mission.
The Muscle Loss Problem Nobody Warned You About
Rapid or significant weight loss of any kind creates a metabolic environment that is, frankly, hostile to muscle. When you’re eating less — whether because of appetite suppression from a GLP-1 medication, willpower, or a structured diet protocol — your body doesn’t shed fat exclusively. It catabolizes lean tissue as well, and the degree to which that happens depends on several variables: protein intake, resistance training, and your metabolic baseline.
That last variable matters more than most men realize. A 2024 retrospective analysis published in Nutrients examined older males undergoing three months of resistance training combined with protein-based multi-ingredient supplementation and found that obesity and metabolic syndrome were the strongest negative predictors of lean mass gains, with correlation coefficients ranging from -0.36 to -0.68. In plain terms: the more metabolically compromised a man is at the start, the harder his body fights against building or even preserving muscle — even when he’s doing everything right with exercise and protein. This phenomenon is called anabolic resistance, and it’s particularly relevant for men on GLP-1 medications, who often begin treatment with significant metabolic dysfunction.
This is not a reason for despair. It’s a reason to be strategic. And creatine monohydrate is one of the most strategically sound additions a man in this situation can make to his supplement stack.
The same 2025 review from Obesity Pillars explicitly identifies creatine monohydrate as a supplement with meaningful justification for GLP-1 users, specifically noting that when combined with resistance training, creatine monohydrate provides additional strength benefits beyond what protein supplementation alone can deliver. It doesn’t replace protein — it works alongside it through distinct and complementary mechanisms.
What Creatine Actually Does (And Why It Matters Beyond the Gym)
Creatine’s reputation lives in the weight room, but its biology extends well beyond raw strength output. The supplement works primarily by increasing phosphocreatine stores in skeletal muscle, which accelerates the regeneration of ATP — your cells’ primary energy currency — during high-intensity effort. More available energy per rep means you can train harder, recover faster between sets, and sustain performance over a longer training session. Over weeks and months, that translates into greater strength adaptations and better lean mass retention.
For men in a caloric deficit, this matters enormously. Reduced caloric intake impairs training performance, which reduces the anabolic stimulus that protects muscle. Creatine partially buffers that performance decline, helping you maintain training intensity even when you’re eating less than you’d like. It also exerts a cell-volumizing effect by drawing water into muscle cells, which can stimulate protein synthesis pathways and create a more anabolic intracellular environment.
The relevance of creatine extends into the realm of sarcopenia — the progressive loss of muscle mass and strength associated with aging. A 2023 systematic review in Biomedicines examined nutritional and pharmacological strategies for sarcopenia and identified creatine among a short list of supplements — alongside leucine, branched-chain amino acids, omega-3s, and vitamin D — as having demonstrated benefits for skeletal muscle maintenance in sarcopenic populations. Importantly, the same review noted that GLP-1 receptor agonists themselves have been considered in sarcopenia research due to their capacity to alter metabolic parameters and protect against cardiovascular disease while offering some muscle-protective effects. In other words, GLP-1 and creatine may share a complementary role in the broader fight against muscle loss — one working systemically on metabolism, the other working locally in the muscle cell.
The evidence extends further into men dealing with hormone-related metabolic challenges. A 2026 systematic review in JNCI Cancer Spectrum examining dietary interventions for prostate cancer patients on androgen deprivation therapy — a treatment that causes muscle loss, weight gain, and impaired glucose tolerance through mechanisms that parallel many features of obesity — found that creatine trended toward increasing lean muscle mass in this medically compromised population. If creatine can move the needle in men whose testosterone has been pharmacologically suppressed, its utility in men navigating weight loss-driven muscle catabolism becomes even more convincing.
Dosing is straightforward. The standard evidence-based protocol is 3 to 5 grams of creatine monohydrate daily, taken consistently. Loading phases — typically 20 grams per day split across four doses for five to seven days — can saturate muscle stores faster, but they’re optional and increase the likelihood of initial water retention and minor GI discomfort. For men on GLP-1 medications who are already managing nausea and appetite changes, skipping the loading phase and going straight to the maintenance dose of 3 to 5 grams per day is likely the more comfortable approach. Timing is flexible — pre-workout, post-workout, or with a meal all produce comparable results in the long run. Consistency matters more than timing.
Creatine monohydrate is the formulation you want. It is the most studied, most affordable, and most effective form. Despite decades of marketing for alternatives like creatine ethyl ester, buffered creatine, and creatine hydrochloride, none have demonstrated superiority to monohydrate in head-to-head research. Stick with the original.
Building a Complete Strategy Around Creatine
Creatine doesn’t operate in a vacuum, and treating it as a standalone solution misses the point. The 2025 Obesity Pillars review frames supplementation — including creatine — within a broader framework of comprehensive nutritional support during GLP-1 treatment. That framework includes hitting protein targets of 1.2 to 2.0 grams of protein per kilogram of body weight daily, addressing micronutrient gaps through a quality multivitamin, and supporting gut health with fiber and probiotics given the gastrointestinal side effects common with GLP-1 medications.
For men not on GLP-1 medications, this same framework applies — it’s just driven by the universal demands of fat loss rather than medication side effects. When you’re eating in a caloric deficit, protein intake is harder to hit in absolute terms, and the metabolic cost of muscle loss is real regardless of what caused the deficit. The Nutrients analysis reinforced that whey and casein-based protein supplementation outperformed collagen-based alternatives for maintaining musculoskeletal health in men at risk for sarcopenic obesity, even when total daily protein intake exceeded treatment guidelines. Quality of protein — specifically leucine content and amino acid completeness — matters, not just quantity.
Resistance training is non-negotiable in this equation. No supplement combination will preserve muscle through weight loss without a progressive mechanical stimulus. Creatine amplifies the results of training; it does not substitute for it. Two to four sessions of resistance training per week, focused on compound movements that stress large muscle groups, provides the anabolic signal that creatine and protein then support. Men on GLP-1 medications often experience fatigue and reduced appetite in the early months — starting with two sessions per week and building from there is entirely reasonable and more sustainable than trying to maintain a pre-medication volume when energy is compromised.
It’s also worth acknowledging that creatine’s safety profile is exceptional. Decades of research across diverse populations have consistently failed to identify clinically meaningful adverse effects in healthy individuals using standard doses. Concerns about kidney damage have been thoroughly examined and largely dismissed in people with normal renal function. The initial weight gain some men notice — typically one to three pounds in the first week — is intracellular water, not fat, and it reflects the muscle-cell hydration that underpins creatine’s mechanism. For men tracking the scale closely during a GLP-1-driven weight loss phase, setting this expectation upfront prevents unnecessary alarm.
The Takeaway
Creatine monohydrate is one of the most evidence-supported supplements available to men who are serious about body composition — and its relevance only grows when significant weight loss is in the picture. Whether you’re using a GLP-1 medication and need to protect the muscle you’re at risk of losing, or you’re running a traditional fat loss phase and want every advantage in the gym, creatine belongs in the conversation. The science isn’t new, but its application to the current landscape of GLP-1-driven weight loss and metabolic health optimization is being validated with increasing specificity. Take 3 to 5 grams daily, lift weights with intention, hit your protein targets, and let the biology work in your favor.
Scientific References
-
Johnson, Milstead, Kreider et al. (2025).
Dietary supplement considerations during glucagon-like Peptide-1 receptor agonist treatment: A narrative review..
Obesity pillars.
View on PubMed → -
Nilsson, Xhuti, de Maat et al. (2024).
Obesity and Metabolic Disease Impair the Anabolic Response to Protein Supplementation and Resistance Exercise: A Retrospective Analysis of a Randomized Clinical Trial with Implications for Aging, Sarcopenic Obesity, and Weight Management..
Nutrients.
View on PubMed → -
Mellen, Girotto, Marques et al. (2023).
Insights into Pathogenesis, Nutritional and Drug Approach in Sarcopenia: A Systematic Review..
Biomedicines.
View on PubMed → -
Pahulu, Calumpit, Tominez et al. (2026).
Diet, nutrition, and hormone therapy for prostate cancer: a systematic review with implications for future interventions..
JNCI cancer spectrum.
View on PubMed → -
Petrilla, Mátis, Kulcsár et al. (2018).
Effect of dietary cereal type, crude protein and butyrate supplementation on metabolic parameters of broilers..
Acta veterinaria Hungarica.
View on PubMed →